Formycon AG
A biopharmaceutical company developing high-quality biosimilars for complex medicines.
FYB | F
Overview
Corporate Details
- ISIN(s):
- DE000A1EWVY8
- LEI:
- 39120005TZ76GQOY8Z19
- Country:
- Germany
- Address:
- Fraunhoferstraße 15, 82152 Planegg
- Website:
- https://www.formycon.com/en/
- Sector:
- Manufacturing
Description
Formycon AG is an independent, globally operating biopharmaceutical company specializing in the development of high-quality biosimilars. As a pure-play biosimilar developer, the company focuses on creating follow-on products for complex biopharmaceutical medicines after their patent protection has expired. The core mission is to enhance patient access to safe, effective, and affordable biologic therapies. Formycon's development activities are concentrated in therapeutic areas with high medical need, including ophthalmology and immunology. The company manages the entire development process, from analytics and process development to clinical trials and regulatory approval submissions for its biosimilar candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-23 14:02 |
FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco Strengthe…
|
English | 15.1 KB | ||
| 2025-12-09 13:04 |
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB2…
|
English | 16.6 KB | ||
| 2025-12-04 06:30 |
Formycon and MS Pharma sign exclusive commercialization partnership for Keytrud…
|
English | 14.8 KB | ||
| 2025-11-24 06:30 |
NTC becomes commercialization partner for Formycons Eylea biosimilar FYB203/Bai…
|
English | 15.2 KB | ||
| 2025-11-20 06:30 |
Ranibizumab Biosimilar Epruvy launched in Germany
|
English | 15.7 KB | ||
| 2025-11-17 06:30 |
Formycon achieves key development milestone with FYB208: Biosimilar candidate f…
|
English | 16.4 KB | ||
| 2025-11-14 00:00 |
Q3 statement / Q3 financial report 2025
|
English | 227.6 KB | ||
| 2025-11-13 06:30 |
Formycon publishes nine-month results and confirms guidance Pipeline progress …
|
English | 40.1 KB | ||
| 2025-10-30 06:30 |
Formycon invites to Conference Call on 2025 Nine-Month Results and announces Pa…
|
English | 13.7 KB | ||
| 2025-10-21 06:30 |
Formycons FYB201/Ranivisio sets innovative standard as Europes First Ranibizuma…
|
English | 16.6 KB | ||
| 2025-10-16 06:30 |
Actor Pharmaceuticals and Megalabs become partners for the commercialization of…
|
English | 15.5 KB | ||
| 2025-10-08 09:00 | English | 3.8 KB | |||
| 2025-10-08 00:00 |
Hinweis auf Zwischenmitteilung der Geschäftsführung vom 01.07.2025 bis zum 30.0…
|
German | 4.6 KB | ||
| 2025-10-02 06:30 |
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 f…
|
English | 13.8 KB | ||
| 2025-09-30 10:16 |
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
|
English | 4.4 KB |
Automate Your Workflow. Get a real-time feed of all Formycon AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Formycon AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Formycon AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-21 | Seidl, Dr. Andreas | Board | Buy | None | 4,800.00 EUR |
| 2024-04-29 | Mikulcik, Dr. Marc | Close relation | Buy | None | 48,000.00 EUR |
| 2024-04-24 | Glombitza, Dr. Stefan | Board | Buy | None | 97,444.00 EUR |
Peer Companies
